Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience

被引：6

作者：

Hashmi, Hamza ^{[1
]}

Hansen, Doris K. ^{[2
]}

Peres, Lauren C. ^{[3
]}

Puglianini, Omar Alexis Castaneda ^{[4
]}

Freeman, Ciara L. ^{[4
]}

De Avila, Gabriel ^{[4
]}

Sidana, Surbhi ^{[5
]}

Shune, Leyla O. ^{[6
]}

Sborov, Douglas W. ^{[7
]}

Davis, James ^{[1
]}

Wagner, Charlotte B. ^{[8
]}

Kocoglu, M. Hakan ^{[9
]}

Atrash, Shebli ^{[10
]}

Voorhees, Peter M. ^{[11
]}

Simmons, Gary ^{[12
]}

Ferreri, Christopher J. ^{[13
]}

Kalariya, Nilesh ^{[13
]}

Sannareddy, Aishwarya ^{[14
]}

Dima, Danai ^{[15
]}

Khouri, Jack ^{[16
]}

McGuirk, Joseph P. ^{[17
]}

Locke, Frederick L. ^{[4
]}

Baz, Rachid C. ^{[18
]}

Patel, Krina ^{[13
]}

Alsina, Melissa ^{[19
]}

机构：

[1] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[5] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat & Cellular Therap, Dept Med, Stanford, CA USA

[6] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut HMC, Kansas City, KS USA

[7] Univ Utah, Huntsman Canc Inst, Sch Med, Salt Lake City, UT USA

[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[9] Univ Maryland, Baltimore, MD USA

[10] Levine Canc Inst, Charlotte, NC USA

[11] Levine Canc Ctr, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[12] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[14] UT Southwestern Med Ctr, Div Hematol & Oncol, Dallas, TX USA

[15] Cleveland Clin, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH USA

[16] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA

[17] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[19] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-164828

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4642 / 4645

页数：4

共 50 条

[1] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
Hashmi, Hamza
Hansen, Doris K.
Peres, Lauren C.
Puglianini, Omar Castaneda
Freeman, Ciara
De Avila, Gabriel
Sidana, Surbhi
Shune, Leyla
Sborov, Douglas W.
Davis, James
Wagner, Charlotte
Kocoglu, Mehmet H.
Atrash, Shebli
Voorhees, Peter
Simmons, Gary
Ferreri, Christopher
Kalariya, Nilesh
Anderson, Larry D., Jr.
Afrough, Aimaz
Dima, Danai
Khouri, Jack
McGuirk, Joseph
Locke, Frederick L.
Baz, Rachid
Patel, Krina K.
Alsina, Melissa
HAEMATOLOGICA, 2024, 109 (05) : 1514 - 1524
[2] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana, Surbhi
Ahmed, Nausheen
Akhtar, Othman S.
Heim, Michael
Brazauskas, Ruta
Hansen, Doris K.
Ferreri, Christopher
Freeman, Ciara Louise L.
Afrough, Aimaz
Anderson, Larry D., Jr.
Dhakal, Binod
Dhanda, Devender
Gowda, Lohith
Hashmi, Hamza
Harrison, Melanie
Kitali, Amani
Mirza, Sayeef
Patel, Jinalben
Patwardhan, Pallavi
Usmani, Saad Z.
Patel, Krina K.
Ganguly, Siddhartha
Pasquini, Marcelo
BLOOD, 2023, 142
[3] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
Anderson, Larry D., Jr.
FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
[4] Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Hansen, Doris K.
Sidana, Surbhi
Peres, Lauren
Shune, Leyla
Sborov, Douglas W.
Hashmi, Hamza
Kocoglu, Mehmet H.
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher J.
Afrough, Aimaz
Kansagra, Ankit J.
Voorhees, Peter M.
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick L.
Patel, Krina K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Hansen, Doris K.
Sidana, Surbhi
Peres, Lauren C.
Leitzinger, Christelle Colin
Shune, Leyla
Shrewsbury, Alexandria
Gonzalez, Rebecca
Sborov, Douglas W.
Wagner, Charlotte
Dima, Danai
Hashmi, Hamza
Kocoglu, Mehmet H.
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher
Afrough, Aimaz
Kansagra, Ankit
Voorhees, Peter
Baz, Rachid
Khouri, Jack
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick L.
Patel, Krina K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2087 - +
[6] Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
Ravi, Gayathri
Bal, Susan
Godby, Kelly
Giri, Smith
Hebert, Courtney
Parekh, Binita
Steele, JoAnn
Brown, Jessica
Langley, Kathy
Costa, Luciano
BLOOD, 2023, 142
[7] Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the US myeloma CAR T consortium
Afrough, Aimaz
Hashmi, Hamza
Hansen, Doris
Sidana, Surbhi
Ahn, Chul
Dima, Danai
Freeman, Ciara
Puglianini, Omar Castaneda
Kocoglu, M. Hakan
Atrash, Shebli
Voorhees, Peter
Shune, Leyla
Simmons, Gary
Sborov, Douglas
Ferreri, Christopher
Wagner, Charlotte
Patel, Krina
Khouri, Jack
Anderson, Larry
Lin, Yi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S33 - S33
[8] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Mancuso, Katia
Barbato, Simona
Talarico, Marco
Tacchetti, Paola
Zamagni, Elena
Cavo, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
[9] Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Afrough, Aimaz
Hashmi, Hamza
Hansen, Doris K.
Sidana, Surbhi
Ahn, Chul
Dima, Danai
Freeman, Ciara L.
Puglianini, Omar Alexis Castaneda
Kocoglu, Mehmet H.
Atrash, Shebli
Voorhees, Peter M.
Shune, Leyla
Simmons, Gary
Sborov, Douglas W.
Ferreri, Christopher J.
Wagner, Charlotte Burton
Patel, Krina K.
Khouri, Jack
Anderson, Larry D., Jr.
Lin, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).
Stong, Nicholas
Thompson, Ethan
Xu, Amy
Rytlewski, Julie
Amzallag, Arnaud
Campbell, Timothy Brandon
Jagannath, Sundar
Munshi, Nikhil C.
Piasecki, Julia
Basudhar, Debashree
Estevez, Maria Ortiz
Kaiser, Shari
Flynt, Erin
Martin, Nathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →